Director, Portfolio Strategy

Summit Therapeutics•Palo Alto, CA

10h

About The Position

Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland.

Requirements

Bachelors degree in Biotech or related field; advanced degree (MS, PhD) preferred.
Minimum of 10+ years of pharmaceuticals/biotech industry experience working with both qualitative and quantitative research in oncology/pharma market with emphasis on Non-Small Cell Lung cancer and other Solid Tumors is required.
Strong understanding of the Solid Tumor Oncology landscape, including portfolio strategy, market planning, competitive intelligence, forecasting and key therapeutic areas such as lung cancer and colorectal cancer.
Proven ability to identify and collect relevant market, customer, and competitor data; perform quantitative and qualitative analysis; Ability to translate complex findings into actionable market insights and strategic recommendations.
Experience developing and executing primary and secondary market research, with exposure to global markets preferred.
Proven experience leading, managing and executing end-to-end market research: designing research plans, synthesizing findings/insights, presenting, etc.
Experience with advanced spreadsheets, patient-based forecast modeling including dynamic patient models, NPV modeling.
Strong communication and presentation skills.
Skilled at PowerPoint, Excel and similar data tools.
Ability to travel up to 25% of the time, depending on business needs.

Nice To Haves

Experience in facilitating competitive workshops, well-versed in TPP development with program and study teams is a plus.
Use online market research and catalogue findings to databases.

Responsibilities

Lead and drive New Indication strategy and planning in several Oncology indications, working cross-functionally (e.g. Clinical, Regulatory, Commercial) to guide Summit’s portfolio for late-stage clinical development strategy
Develop/refine framework and process for the New indication and overall portfolio strategy, providing thought leadership and supporting key strategic decision-making and investment decisions
Deliver strategic market and competitive intelligence insights through research, scenario planning, and impact assessments to guide executive decision-making and Summit’s portfolio strategy.
Deliver Disease Area strategy for new solid tumor indications by providing an overall integrated strategy and market assessment in partnership with R&D, Clinical, Medical, Commercial and Program teams
Partner with BD team to provide strategic direction and guidance on business development opportunities
Conduct deep analysis of competitors, products, and market trends, maintaining real-time awareness of landscape changes and translating insights into strategic implications for launch and also for pipeline indications
Develop, lead and execute comprehensive market research plans (qualitative, quantitative, and competitive), selecting vendors, designing studies, interpreting results, and ensuring timely, high-quality deliverables.
Develop NPV, forecasting and revenue modeling for new indications up to 18 months before launch, providing data-driven assumptions for early commercial planning.
Lead TPP development and alignment with cross-functional team for several solid tumor indications
Integrate market research and competitive intelligence into strategic planning, including brand plans, market access, and situation analysis.
Maintain an in-depth understanding of oncology markets and data sources, synthesizing findings into a central knowledge repository for organizational use.
Provide ad hoc analytical support to executive stakeholders to inform R&D, commercial, and business development decisions.
Leverage best-class analytical methodologies and tools to interpret epidemiology, market, and customer data into actionable recommendations.
Build and manage external partnerships—from market research vendors to data providers—ensuring quality, accountability, and cost-effectiveness.